{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:38:42Z","timestamp":1790199522540,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00066-023-02189-0","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T12:02:12Z","timestamp":1704456132000},"page":"239-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Stereotactic body radiotherapy (SIB-VMAT technique) to dominant intraprostatic lesion (DIL) for localized prostate cancer: a\u00a0dose-escalation trial (DESTROY-4)."],"prefix":"10.1007","volume":"200","author":[{"given":"Francesco","family":"Deodato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0678-4996","authenticated-orcid":false,"given":"Milena","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bonome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Pezzulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milly","family":"Buwenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Cilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio Giuseppe","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"issue":"12","key":"2189_CR1","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","volume":"17","author":"DR Gomez","year":"2016","unstructured":"Gomez\u00a0DR, Blumenschein\u00a0GR Jr, Lee\u00a0JJ et\u00a0al (2016) Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a\u00a0multicentre, randomised, controlled, phase\u00a02\u00a0study. Lancet Oncol 17(12):1672\u20131682. https:\/\/doi.org\/10.1016\/S1470-2045(16)30532-0","journal-title":"Lancet Oncol"},{"issue":"1","key":"2189_CR2","doi-asserted-by":"publisher","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","volume":"4","author":"P Iyengar","year":"2018","unstructured":"Iyengar\u00a0P, Wardak\u00a0Z, Gerber\u00a0DE et\u00a0al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a\u00a0phase\u00a02 randomized clinical trial. JAMA Oncol 4(1):e173501. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3501","journal-title":"JAMA Oncol"},{"issue":"5","key":"2189_CR3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips\u00a0R, Shi\u00a0WY, Deek\u00a0M et\u00a0al (2020) Outcomes of observation vs Stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase\u00a02 randomized clinical trial. JAMA Oncol 6(5):650\u2013659. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147","journal-title":"JAMA Oncol"},{"issue":"25","key":"2189_CR4","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma\u00a0DA, Olson\u00a0R, Harrow\u00a0S et\u00a0al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase\u00a0II randomized trial. J\u00a0Clin Oncol 38(25):2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"},{"issue":"5","key":"2189_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost\u00a0P, Reynders\u00a0D, Decaestecker\u00a0K et\u00a0al (2018) Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a\u00a0prospective, randomized, multicenter phase\u00a0II trial. J\u00a0Clin Oncol 36(5):446\u2013453. https:\/\/doi.org\/10.1200\/JCO.2017.75.4853","journal-title":"J Clin Oncol"},{"issue":"2","key":"2189_CR6","doi-asserted-by":"publisher","first-page":"e311","DOI":"10.1634\/theoncologist.2019-0309","volume":"25","author":"G Macchia","year":"2020","unstructured":"Macchia\u00a0G, Lazzari\u00a0R, Colombo\u00a0N et\u00a0al (2020) A large, multicenter, retrospective study on efficacy and safety of Stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study): a\u00a0collaboration of MITO, AIRO GYN, and maNGO groups. Oncologist 25(2):e311\u2013e320. https:\/\/doi.org\/10.1634\/theoncologist.2019-0309","journal-title":"Oncologist"},{"key":"2189_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.04.025","author":"G Macchia","year":"2023","unstructured":"Macchia\u00a0G, Pezzulla\u00a0D, Campitelli\u00a0M et\u00a0al (2023) Efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic uterine cancer (MITO-RT2\/RAD STUDY): a\u00a0large, real-world study in collaboration with AIRO GYN, MITO and MaNGO Groups. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.04.025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","volume":"50","author":"J Fowler","year":"2001","unstructured":"Fowler\u00a0J, Chappell\u00a0R, Ritter\u00a0M (2001) Is alpha\/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021\u20131031","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","volume":"43","author":"DJ Brenner","year":"1999","unstructured":"Brenner\u00a0DJ, Hall\u00a0EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095\u20131101","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0360-3016(01)01650-9","volume":"51","author":"WD D\u2019Souza","year":"2001","unstructured":"D\u2019Souza\u00a0WD, Thames\u00a0HD (2001) Is the alpha\/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51:1\u20133","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.clon.2007.02.007","volume":"19","author":"A Dasu","year":"2007","unstructured":"Dasu\u00a0A (2007) Is the alpha\/beta value for prostate tumours low enough to be safely used in clinical trials? Clin Oncol 19:289\u2013301","journal-title":"Clin Oncol"},{"key":"2189_CR12","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","volume":"17","author":"D Dearnaley","year":"2016","unstructured":"Dearnaley\u00a0D, Syndikus\u00a0I, Mossop\u00a0H et\u00a0al (2016) Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5\u2011year outcomes of the randomised, non-inferiority, phase\u00a03 CHHiP trial. Lancet Oncol 17:1047\u20131060","journal-title":"Lancet Oncol"},{"key":"2189_CR13","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/S1470-2045(16)30070-5","volume":"17","author":"L Incrocci","year":"2016","unstructured":"Incrocci\u00a0L, Wortel\u00a0RC, Alemayehu\u00a0WG et\u00a0al (2016) Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a\u00a0randomised, multicentre, open-label, phase\u00a03\u00a0trial. Lancet Oncol 17:1061\u20131069","journal-title":"Lancet Oncol"},{"key":"2189_CR14","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1200\/JCO.2016.67.0448","volume":"34","author":"WR Lee","year":"2016","unstructured":"Lee\u00a0WR, Dignam\u00a0JJ, Amin\u00a0MB et\u00a0al (2016) Randomized phase\u00a0III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J\u00a0Clin Oncol 34:2325\u20132332","journal-title":"J Clin Oncol"},{"key":"2189_CR15","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1200\/JCO.2016.71.7397","volume":"35","author":"CN Catton","year":"2017","unstructured":"Catton\u00a0CN, Lukka\u00a0H, Gu\u00a0CS et\u00a0al (2017) Randomized trial of a\u00a0hypofractionated radiation regimen for the treatment of localized prostate cancer. J\u00a0Clin Oncol 35:1884\u20131890","journal-title":"J Clin Oncol"},{"key":"2189_CR16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.radonc.2018.02.029","volume":"127","author":"HC Quon","year":"2018","unstructured":"Quon\u00a0HC, Ong\u00a0A, Cheung\u00a0P et\u00a0al (2018) Once weekly versus every-other-day stereotactic body radiotherapy in patients with prostate cancer (PATRIOT): a\u00a0phase\u00a02 randomized trial. Radiother Oncol 127:206\u2013212. https:\/\/doi.org\/10.1016\/j.radonc.2018.02.029","journal-title":"Radiother Oncol"},{"key":"2189_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark\u00a0A, Gunnlaugsson\u00a0A, Beckman\u00a0L et\u00a0al (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5\u2011year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase\u00a03\u00a0trial. Lancet 394:385\u2013395. https:\/\/doi.org\/10.1016\/S0140-6736(19)31131-6","journal-title":"Lancet"},{"key":"2189_CR18","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ijrobp.2014.03.012","volume":"89","author":"DWN Kim","year":"2014","unstructured":"Kim\u00a0DWN, Cho\u00a0LC, Straka\u00a0C et\u00a0al (2014) Predictors of rectal tolerance observed in a\u00a0dose-escalated phase\u00a01\u20132\u00a0trial of stereotactic body radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 89:509\u2013517. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.03.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR19","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2010.31.4377","volume":"29","author":"TP Boike","year":"2011","unstructured":"Boike\u00a0TP, Lotan\u00a0Y, Cho\u00a0LC et\u00a0al (2011) Phase\u00a0I dose escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer. J\u00a0Clin Oncol 29:2020\u20132026. https:\/\/doi.org\/10.1200\/JCO.2010.31.4377","journal-title":"J Clin Oncol"},{"issue":"10","key":"2189_CR20","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree\u00a0AC, Ostler\u00a0P, van der Voet\u00a0H et\u00a0al (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2\u2011year toxicity results from an open-label, randomised, phase\u00a03, non-inferiority trial. Lancet Oncol 23(10):1308\u20131320. https:\/\/doi.org\/10.1016\/S1470-2045(22)00517-4","journal-title":"Lancet Oncol"},{"key":"2189_CR21","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer, Version\u00a01.2023"},{"issue":"3","key":"2189_CR22","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/s0360-3016(02)02795-5","volume":"53","author":"N Cellini","year":"2002","unstructured":"Cellini\u00a0N, Morganti\u00a0AG, Mattiucci\u00a0GC et\u00a0al (2002) Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys 53(3):595\u2013599. https:\/\/doi.org\/10.1016\/s0360-3016(02)02795-5","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR23","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.eururo.2010.12.009","volume":"59","author":"L Dickinson","year":"2011","unstructured":"Dickinson\u00a0L, Ahmed\u00a0HU, Allen\u00a0C et\u00a0al (2011) Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a\u00a0European consensus meeting. Eur Urol 59:477\u2013494. https:\/\/doi.org\/10.1016\/j.eururo.2010.12.009","journal-title":"Eur Urol"},{"key":"2189_CR24","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3389\/fonc.2019.00616","volume":"9","author":"J Lee","year":"2019","unstructured":"Lee\u00a0J, Carver\u00a0E, Feldman\u00a0A et\u00a0al (2019) Volumetric and voxel-wise analysis of dominant Intraprostatic lesions on multiparametric MRI. Front Oncol 9:616. https:\/\/doi.org\/10.3389\/fonc.2019.00616","journal-title":"Front Oncol"},{"issue":"4","key":"2189_CR25","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.meddos.2019.01.008","volume":"44","author":"S Ciabatti","year":"2019","unstructured":"Ciabatti\u00a0S, Ntreta\u00a0M, Buwenge\u00a0M et\u00a0al (2019) Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A\u00a0planning feasibility study. Med Dosim 44(4):356\u2013364","journal-title":"Med Dosim"},{"key":"2189_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/1748-717X-8-84","volume":"8","author":"S Aluwini","year":"2013","unstructured":"Aluwini\u00a0S, van Rooij\u00a0P, Hoogeman\u00a0M et\u00a0al (2013) Stereotactic body radiotherapy with a\u00a0focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results. Radiat Oncol 8:84. https:\/\/doi.org\/10.1186\/1748-717X-8-84","journal-title":"Radiat Oncol"},{"issue":"1","key":"2189_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.adro.2018.09.007","volume":"4","author":"AM McDonald","year":"2018","unstructured":"McDonald\u00a0AM, Dobelbower\u00a0MC, Yang\u00a0ES et\u00a0al (2018) Prostate stereotactic body radiation therapy with a\u00a0focal simultaneous integrated boost: acute toxicity and dosimetry results from a\u00a0prospective trial. Adv Radiat Oncol 4(1):90\u201395. https:\/\/doi.org\/10.1016\/j.adro.2018.09.007","journal-title":"Adv Radiat Oncol"},{"key":"2189_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","volume":"147","author":"C Draulans","year":"2020","unstructured":"Draulans\u00a0C, van der Heide\u00a0UA, Haustermans\u00a0K et\u00a0al (2020) Primary endpoint analysis of the multicentre phase\u00a0II hypo-FLAME trial for intermediate and high-risk prostate cancer. Radiother Oncol 147:92\u201398. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.015","journal-title":"Radiother Oncol"},{"issue":"2","key":"2189_CR29","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ijrobp.2018.09.023","volume":"103","author":"FG Herrera","year":"2019","unstructured":"Herrera\u00a0FG, Valerio\u00a0M, Berthold\u00a0D et\u00a0al (2019) 50-Gy stereotactic body radiation therapy to the dominant Intraprostatic nodule: results from a\u00a0phase\u00a01a\/b trial. Int J Radiat Oncol Biol Phys 103(2):320\u2013334. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.09.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2189_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ijrobp.2016.02.009","volume":"95","author":"R Kotecha","year":"2016","unstructured":"Kotecha\u00a0R, Djemil\u00a0T, Tendulkar\u00a0RD et\u00a0al (2016) Dose-escalated stereotactic body radiation therapy for patients with intermediate- and high-risk prostate cancer: initial dosimetry analysis and patient outcomes. Int J Radiat Oncol Biol Phys 95(3):960\u2013964. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.02.009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2189_CR31","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ijrobp.2016.07.004","volume":"96","author":"G Macchia","year":"2016","unstructured":"Macchia\u00a0G, Cilla\u00a0S, Deodato\u00a0F et\u00a0al (2016) Simultaneous integrated boost volumetric modulated arc therapy in the postoperative treatment of high-risk to intermediate-risk endometrial cancer: results of ADA II phase\u00a01\u20132 trial. Int J Radiat Oncol Biol Phys 96(3):606\u2013613. https:\/\/doi.org\/10.1016\/j.ijrobp.2016.07.004","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2189_CR32","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.meddos.2013.11.001","volume":"39","author":"S Cilla","year":"2014","unstructured":"Cilla\u00a0S, Deodato\u00a0F, Diges\u00f9\u00a0C et\u00a0al (2014) Assessing the feasibility of volumetric-modulated arc therapy using simultaneous integrated boost (SIB-VMAT): An analysis for complex head-neck, high risk prostate and rectal cancer cases. Med Dosim 39(1):108\u2013116. https:\/\/doi.org\/10.1016\/j.meddos.2013.11.001","journal-title":"Med Dosim"},{"issue":"5","key":"2189_CR33","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","volume":"148","author":"MJ Barry","year":"1992","unstructured":"Barry\u00a0MJ, Fowler\u00a0FJ Jr, O\u2019Leary\u00a0MP et\u00a0al (1992) The American Urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association. J\u00a0Urol 148(5):1549\u20131557","journal-title":"J Urol"},{"issue":"1","key":"2189_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.eururo.2015.08.052","volume":"69","author":"JC Weinreb","year":"2016","unstructured":"Weinreb\u00a0JC, Barentsz\u00a0JO, Choyke\u00a0PL et\u00a0al (2016) PI-RADS prostate imaging\u2014reporting and data system: 2015, version\u00a02. Eur Urol 69(1):16\u201340","journal-title":"Eur Urol"},{"key":"2189_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s13566-018-0371-6","volume":"1","author":"TM Ma","year":"2019","unstructured":"Ma\u00a0TM, Emami\u00a0B, Grimm\u00a0J et\u00a0al (2019) Volume effects in radiosurgical spinal cord dose tolerance: how small is too small? J\u00a0Radiat Oncol 1:53\u201361","journal-title":"J Radiat Oncol"},{"issue":"3","key":"2189_CR36","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.juro.2011.04.085","volume":"186","author":"P Chang","year":"2011","unstructured":"Chang\u00a0P, Szymanski\u00a0KM, Dunn\u00a0RL et\u00a0al (2011) Expanded prostate cancer index composite for clinical practice: development and validation of a\u00a0practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J\u00a0Urol 186(3):865\u2013872. https:\/\/doi.org\/10.1016\/j.juro.2011.04.085","journal-title":"J Urol"},{"issue":"1","key":"2189_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0167-8140(99)00173-5","volume":"54","author":"S Wachter","year":"2000","unstructured":"Wachter\u00a0S, Gerstner\u00a0N, Goldner\u00a0G et\u00a0al (2000) Endoscopic scoring of late rectal mucosal damage after conformal radiotherapy for prostatic carcinoma. Radiother Oncol 54(1):11\u201319. https:\/\/doi.org\/10.1016\/s0167-8140(99)00173-5","journal-title":"Radiother Oncol"},{"issue":"5","key":"2189_CR38","doi-asserted-by":"publisher","first-page":"961","DOI":"10.21873\/invivo.11154","volume":"31","author":"E Ippolito","year":"2017","unstructured":"Ippolito\u00a0E, Guido\u00a0A, Macchia\u00a0G et\u00a0al (2017) Predictive factors of late-onset rectal mucosal changes after radiotherapy of prostate cancer. In Vivo 31(5):961\u2013966. https:\/\/doi.org\/10.21873\/invivo.11154","journal-title":"In Vivo"},{"issue":"1","key":"2189_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/s0360-3016(00)00603-9","volume":"48","author":"S Malone","year":"2000","unstructured":"Malone\u00a0S, Crook\u00a0JM, Kendal\u00a0WS et\u00a0al (2000) Respiratory-induced prostate motion: quantification and characterization. Int J Radiat Oncol Biol Phys 48(1):105\u2013109. https:\/\/doi.org\/10.1016\/s0360-3016(00)00603-9","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.phro.2018.03.008","volume":"5","author":"EPP Pang","year":"2018","unstructured":"Pang\u00a0EPP, Knight\u00a0K, Fan\u00a0Q et\u00a0al (2018) Analysis of intra-fraction prostate motion and derivation of duration-dependent margins for radiotherapy using real-time 4D ultrasound. Phys Imaging Radiat Oncol 5:102\u2013107. https:\/\/doi.org\/10.1016\/j.phro.2018.03.008","journal-title":"Phys Imaging Radiat Oncol"},{"issue":"4","key":"2189_CR41","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/s0360-3016(03)00132-9","volume":"56","author":"JF Fowler","year":"2003","unstructured":"Fowler\u00a0JF, Ritter\u00a0MA, Chappell\u00a0RJ et\u00a0al (2003) What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 56(4):1093\u20131104. https:\/\/doi.org\/10.1016\/s0360-3016(03)00132-9","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR42","doi-asserted-by":"publisher","first-page":"109713","DOI":"10.1016\/j.radonc.2023.109713","volume":"185","author":"L De Cock","year":"2023","unstructured":"De Cock\u00a0L, Draulans\u00a0C, Pos\u00a0FJ et\u00a0al (2023) From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase\u00a0II hypo-FLAME 2.0\u00a0trial. Radiother Oncol 185:109713. https:\/\/doi.org\/10.1016\/j.radonc.2023.109713","journal-title":"Radiother Oncol"},{"key":"2189_CR43","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1259\/bjr.20180422","volume":"92","author":"F Deodato","year":"2019","unstructured":"Deodato\u00a0F, Macchia\u00a0G, Cilla\u00a0S et\u00a0al (2019) Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): a\u00a0multiarm phase\u00a0I trial. Br J Radiol 92:1094","journal-title":"Br J Radiol"},{"key":"2189_CR44","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/07357907.2011.640649","volume":"30","author":"G Macchia","year":"2012","unstructured":"Macchia\u00a0G, Morganti\u00a0AG, Cilla\u00a0S et\u00a0al (2012) Quality of life and toxicity of stereotactic radiotherapy in pancreatic tumors: a\u00a0case series. Cancer Invest 30:149\u2013155. https:\/\/doi.org\/10.3109\/07357907.2011.640649","journal-title":"Cancer Invest"},{"issue":"4","key":"2189_CR45","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10585-020-10039-x","volume":"37","author":"F Deodato","year":"2020","unstructured":"Deodato\u00a0F, Ferro\u00a0M, Cilla\u00a0S et\u00a0al (2020) Stereobody radiotherapy for nodal recurrences in oligometastatic patients: a\u00a0pooled analysis from two phase\u00a0I clinical trials. Clin Exp Metastasis 37(4):519\u2013529. https:\/\/doi.org\/10.1007\/s10585-020-10039-x","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"2189_CR46","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s10585-021-10126-7","volume":"38","author":"D Pezzulla","year":"2021","unstructured":"Pezzulla\u00a0D, Macchia\u00a0G, Cilla\u00a0S et\u00a0al (2021) Stereotactic body radiotherapy to lymph nodes in oligoprogressive castration-resistant prostate cancer patients: a\u00a0post hoc analysis from two phase\u00a0I clinical trials. Clin Exp Metastasis 38(6):519\u2013526. https:\/\/doi.org\/10.1007\/s10585-021-10126-7","journal-title":"Clin Exp Metastasis"},{"key":"2189_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.05.004","author":"JA Maas","year":"2023","unstructured":"Maas\u00a0JA, Dobelbower\u00a0MC, Yang\u00a0ES et\u00a0al (2023) Prostate stereotactic body radiation therapy with a\u00a0focal simultaneous integrated boost: five year toxicity and biochemical recurrence results from a\u00a0prospective trial: prostate SBRT with focal SIB: 5 year results. Pract Radiat Oncol. https:\/\/doi.org\/10.1016\/j.prro.2023.05.004","journal-title":"Pract Radiat Oncol"},{"issue":"2","key":"2189_CR48","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/j.ijrobp.2011.12.046","volume":"83","author":"E Ippolito","year":"2012","unstructured":"Ippolito\u00a0E, Massaccesi\u00a0M, Diges\u00f9\u00a0C et\u00a0al (2012) Early proctoscopy is a\u00a0surrogate endpoint of late rectal toxicity in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 83(2):e191\u2013e195. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.12.046","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1748-717X-8-58","volume":"8","author":"LN Chen","year":"2013","unstructured":"Chen\u00a0LN, Suy\u00a0S, Uhm\u00a0S et\u00a0al (2013) Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol 8:58","journal-title":"Radiat Oncol"},{"key":"2189_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2490-10-1","volume":"10","author":"AJ Katz","year":"2010","unstructured":"Katz\u00a0AJ, Santoro\u00a0M, Ashley\u00a0R et\u00a0al (2010) Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol 10:1","journal-title":"BMC Urol"},{"key":"2189_CR51","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1186\/s13014-014-0277-4","volume":"9","author":"DY Joh","year":"2014","unstructured":"Joh\u00a0DY, Chen\u00a0LN, Porter\u00a0G et\u00a0al (2014) Proctitis following stereotactic body radiation therapy for prostate cancer. Radiat Oncol 9:277. https:\/\/doi.org\/10.1186\/s13014-014-0277-4","journal-title":"Radiat Oncol"},{"key":"2189_CR52","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ijrobp.2006.08.055","volume":"67","author":"G Goldner","year":"2007","unstructured":"Goldner\u00a0G, Tomicek\u00a0B, Becker\u00a0G et\u00a0al (2007) Proctitis after external-beam radiotherapy for prostate cancer classified by Vienna Rectoscopy Score and correlated with EORTC\/RTOG score for late rectal toxicity: results of a\u00a0prospective multicenter study of 166 patients. Int J Radiat Oncol Biol Phys 67:78\u201383","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR53","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.ijrobp.2006.09.034","volume":"67","author":"EN van Lin","year":"2007","unstructured":"van Lin\u00a0EN, Kristinsson\u00a0J, Philippens\u00a0ME et\u00a0al (2007) Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon as observed in repeated endoscopy. Int J Radiat Oncol Biol Phys 67:799\u2013811","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR54","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.ijrobp.2005.07.006","volume":"64","author":"ME Ray","year":"2006","unstructured":"Ray\u00a0ME, Thames\u00a0HD, Levy\u00a0LB et\u00a0al (2006) PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a\u00a0multi-institutional analysis. Int J Radiat Oncol Biol Phys 64:1140\u20131150","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2189_CR55","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/cncr.22341","volume":"109","author":"P Alcantara","year":"2007","unstructured":"Alcantara\u00a0P, Hanlon\u00a0A, Buyyounouski\u00a0MK et\u00a0al (2007) Prostate specific antigen nadir within 12\u00a0months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109:41\u201347","journal-title":"Cancer"},{"key":"2189_CR56","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1056\/NEJMoa074311","volume":"358","author":"MG Sanda","year":"2008","unstructured":"Sanda\u00a0MG, Dunn\u00a0RL, Michalski\u00a0J et\u00a0al (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N\u00a0Engl J Med 358:1250\u20131261","journal-title":"N Engl J Med"},{"issue":"2","key":"2189_CR57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","volume":"197","author":"F Wolf","year":"2021","unstructured":"Wolf\u00a0F, Sedlmayer\u00a0F, Aebersold\u00a0D et\u00a0al (2021) Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 197(2):89\u201396","journal-title":"Strahlenther Onkol"},{"issue":"2","key":"2189_CR58","doi-asserted-by":"publisher","first-page":"djv305","DOI":"10.1093\/jnci\/djv305","volume":"108","author":"JD Zindler","year":"2015","unstructured":"Zindler\u00a0JD, Thomas\u00a0CR Jr, Hahn\u00a0SM et\u00a0al (2015) Increasing the therapeutic ratio of stereotactic ablative radiotherapy by individualized Isotoxic dose prescription. J\u00a0Natl Cancer Inst 108(2):djv305. https:\/\/doi.org\/10.1093\/jnci\/djv305","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"2189_CR59","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.3390\/cancers13225795","volume":"13","author":"C Zamboglou","year":"2021","unstructured":"Zamboglou\u00a0C, Spohn\u00a0SKB, Adebahr\u00a0S et\u00a0al (2021) PSMA-PET\/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (hypofocal-SBRT): study protocol of a\u00a0randomized, Multicentric phase\u00a0III trial. Cancers 13(22):5795. https:\/\/doi.org\/10.3390\/cancers13225795","journal-title":"Cancers"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-023-02189-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-023-02189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T16:03:41Z","timestamp":1708358621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-023-02189-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2189"],"URL":"https:\/\/doi.org\/10.1007\/s00066-023-02189-0","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]},"assertion":[{"value":"27 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"F.\u00a0Deodato, M.\u00a0Ferro, P.\u00a0Bonome, D.\u00a0Pezzulla, C.\u00a0Romano, M.\u00a0Buwenge, S.\u00a0Cilla, A.G.\u00a0Morganti and G.\u00a0Macchia declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"For all procedures performed in studies involving human participants or on human tissue Approval was obtained from the Institutional Review Board of Gemelli Molise Hospital and adhere to the tenets of the 1875 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}